Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Prepaid Assets (2020 - 2025)

Caribou Biosciences has reported Prepaid Assets over the past 6 years, most recently at $2.9 million for Q4 2025.

  • Quarterly Prepaid Assets fell 55.79% to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Dec 2025, down 55.79% year-over-year, with the annual reading at $2.9 million for FY2025, 55.79% down from the prior year.
  • Prepaid Assets was $2.9 million for Q4 2025 at Caribou Biosciences, down from $5.3 million in the prior quarter.
  • Over five years, Prepaid Assets peaked at $8.6 million in Q3 2022 and troughed at $966000.0 in Q1 2022.
  • The 5-year median for Prepaid Assets is $6.1 million (2023), against an average of $5.9 million.
  • Year-over-year, Prepaid Assets surged 658.49% in 2021 and then tumbled 55.79% in 2025.
  • A 5-year view of Prepaid Assets shows it stood at $7.2 million in 2021, then rose by 9.47% to $7.9 million in 2022, then decreased by 22.3% to $6.2 million in 2023, then increased by 7.05% to $6.6 million in 2024, then tumbled by 55.79% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Prepaid Assets are $2.9 million (Q4 2025), $5.3 million (Q3 2025), and $5.8 million (Q2 2025).